WO2022064478A1 - Formulations hémostatiques et leurs utilisations - Google Patents

Formulations hémostatiques et leurs utilisations Download PDF

Info

Publication number
WO2022064478A1
WO2022064478A1 PCT/IL2021/051112 IL2021051112W WO2022064478A1 WO 2022064478 A1 WO2022064478 A1 WO 2022064478A1 IL 2021051112 W IL2021051112 W IL 2021051112W WO 2022064478 A1 WO2022064478 A1 WO 2022064478A1
Authority
WO
WIPO (PCT)
Prior art keywords
factor
formulation
bleeding
protein
vitamin
Prior art date
Application number
PCT/IL2021/051112
Other languages
English (en)
Inventor
Israel Nur
Roni Mintz
Damian Visnovezky
Marina YUNUSOV
Michael LESHETS
Original Assignee
Omrix Biopharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omrix Biopharmaceuticals Ltd. filed Critical Omrix Biopharmaceuticals Ltd.
Priority to CN202180064844.0A priority Critical patent/CN116194080A/zh
Priority to AU2021348528A priority patent/AU2021348528A1/en
Priority to EP21801233.4A priority patent/EP4216928A1/fr
Publication of WO2022064478A1 publication Critical patent/WO2022064478A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Definitions

  • the present disclosure inter alia relates to hemostatic formulations and uses thereof.
  • US Patent No. 9,814,765 describes a single component sealant formulation (e.g. in a liquid form) that includes fibrinogen; vitamin K-dependent clotting zymogens comprising at least Factor II (FII) and Factor X (FX), methods for its preparation, and use.
  • FII Factor II
  • FX Factor X
  • US Patent No. 7,371 ,722 relates to a pharmaceutically active substance containing (A) prothrombin (coagulation factor II) obtained from plasma or by genetic engineering, (B) coagulation factors V, VIII, IX, X obtained from plasma or by genetic engineering that at least partially may be present in their activated state, and coagulation factor Xia obtained from plasma or by genetic engineering, and (C) prion-safe, coagulationpromoting phospholipids, the active substance is for producing a drug that is capable of generating thrombin or that contains thrombin and compositions comprising thereof.
  • prothrombin coagulation factor II
  • V, VIII, IX, X obtained from plasma or by genetic engineering that at least partially may be present in their activated state
  • coagulation factor Xia obtained from plasma or by genetic engineering
  • C prion-safe, coagulationpromoting phospholipids
  • US Patent Application No. 2018/0036338 relates to hemostatic compositions comprising polysaccharide-based polymers, such as amylopectins, amylose, dextrins, maltodextrins and icodextrin and modified forms thereof, cross-linked with a crosslinking agent that are useful as a hemostatic composition.
  • polysaccharide-based polymers such as amylopectins, amylose, dextrins, maltodextrins and icodextrin and modified forms thereof, cross-linked with a crosslinking agent that are useful as a hemostatic composition.
  • US Patent No. 5,866,122 describes a pharmaceutical preparation for treating blood coagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component.
  • US Patent No. 3,560,475 describes a prothrombin complex prepared from a plasma fraction containing Factors II, VII, IX and X by adsorption with tribasic calcium phosphate, elution with trisodium citrate, and multiple precipitations with polyethylene glycol.
  • US Patent Application No. 2018/0369346 provides a composition, comprising: proaccelerin (factor V) and at least one factor selected from the group consisting of: prothrombin (factor II), proconvertin (factor VII), and Stuart-Prower factor (factor X).
  • US Patent No. RE38431 relates to stable liquid formulations of Factor VIII and Factor IX that can be administered by injection or infusion to provide a constant level of the coagulation factor in the blood.
  • US Patent Application No. 2014/0155498 describes diagnostic or therapeutic formulation of stable liquid coagulation factors comprises at least one coagulation factor, at least one stabilizer, and optional additives.
  • the present disclosure is based on the development of a formulation that comprises coagulation factors in a zymogen form (i.e. inactive form) and is stable when stored in liquid form.
  • a formulation comprising concentrated Factor V, at least one vitamin K-dependent clotting protein and at least one stabilizer, wherein the at least one stabilizer is at a concentration at which the Factor V and/or the at least one vitamin K-dependent clotting protein are in a zymogen form.
  • the present disclosure also provides in accordance with a further aspect, a formulation comprising concentrated Factor V, at least one vitamin K-dependent clotting protein and free calcium ions at a concentration of at most about 5mM, for example less than 5mM.
  • the present disclosure also provides in accordance with a further aspect, a formulation comprising concentrated Factor V, Factor II, Factor VII, Factor IX and Factor X and free calcium ions at a concentration of less than about 5mM, for example in the range of O.lmM and less than 5mM.
  • the present disclosure also provides, in accordance with a further aspect, a formulation comprising concentrated Factor V and one or more co-purified vitamin K- dependent clotting protein selected from Factor II, Factor VII, Factor IX and Factor X and free calcium ions, the free calcium ions being at a concentration of less than about 5mM, for example in the range of O.lmM and less than 5mM.
  • This formulation does not include exogenously added vitamin K-dependent clotting proteins selected from Factor II, Factor VII, Factor IX and Factor X.
  • the present disclosure also provides, in accordance with a further aspect, a formulation comprising concentrated Factor V, Factor II, Factor VII, Factor IX and Factor X and free calcium ions, the free calcium ions being at a concentration of less than about 5mM, for example in the range of O.lmM and less than 5mM.
  • This formulation does not include exogenously added vitamin K-dependent clotting proteins selected from Factor II, Factor VII, Factor IX and Factor X.
  • the ratio between Factor V, Factor II, Factor VII, Factor IX and Factor X is:
  • Factor V not less than 0.5: Factor II about 1: Factor VII about l:Factor IX about 1 and: Factor X about 1;
  • 0.5 may be e.g. 0.5, 0.6, 0.7, 0.8, 0.9 or e.g. in the range of 0.7-0.8 or 0.5 to 1 and including any value therebetween.
  • the ratio between Factor V, and at least one of Factor II, Factor VII, Factor IX and Factor X is:
  • Factor V to at least one member from Factor II, Factor VII , Factor IX, Factor X being in a respective ratio of Factor V being not less than 0.5 to the at least one member being about 1.
  • the factors are non-activated.
  • composition may further comprise antithrombin III, heparin, protein C, and/or Protein S.
  • the present disclosure provides a method for the treatment, inhibition, arresting or delaying bleeding or any disorder associated thereto in a subject in need thereof.
  • the method of the invention comprises the step of administering to the subject an effective amount of a formulation as disclosed.
  • the present disclosure provides a formulation comprising concentrated Factor V, at least one vitamin K-dependent clotting protein and at least one stabilizer for use in the treatment, inhibition, arresting or delaying bleeding or any disorder associated thereto in a subject in need thereof, the at least one stabilizer is present at a concentration at which the Factor V and/or the at least one vitamin K-dependent clotting protein are in zymogen form.
  • the present disclosure also relates in accordance with some further aspect, to a kit comprising a formulation as disclosed herein, and optionally instructions for use of the formulation to treatment, inhibition, arresting or delaying bleeding or any disorder associated thereto.
  • a process for the preparation of a formulation comprising concentrated Factor V and at least one vitamin K-dependent clotting protein comprising (i) subjecting blood, plasma or any product/fraction thereof to at least one separation step and (ii) recovering the Factor V and at least one vitamin K-dependent clotting protein obtained in step (i).
  • the at least one separation step comprises at least one chromatography step.
  • the recovery comprises eluting a fraction bound to the at least one anion exchange chromatography with an elution solution into a collection solution.
  • Fig. 1 is a bar graph showing the total level of procoagulants and inhibitors in the elution fraction in Units per ml of load at pH 8.0 by different AEX resins in batch mode, from left to right, the factors aligned FII, FV, FVII, FIX, FX, Protein C, Protein S and Antithrombin III (if present).
  • Fig. 2 is a bar graph showing the percentage recoveries of FII, FV and FIX (from bottom to upper fragment in each bar) in 20cm height AEX columns, all columns with a diameter of 1.0 cm, except for C61R2, with 2.6 cm.
  • Fig. 3 is a graph showing the levels of procoagulants and inhibitors determined in the elution fraction as percentage of recovery (Elution/Load) of the different runs in the Design of Experiment (DOE) using a prepacked Eshmuno Q column of 0.8cm width by 10cm (Merck), from left to right, the factors aligned FII, FV, FVII, FIX, FX, Protein S, Protein C and Antithrombin III (if present).
  • Figs. 4A and 4B are bar graphs showing the amount of FII (Fig. 4A) and FV (Fig. 4B) observed after 24 hours incubation at different temperatures (from left to right: -65 °C, shown only at pH 6.7; Room Temperature; and 2-8 °C) at pH 6.7, 7.2 and 7.7.
  • Fig. 5 is a bar graph showing the amount (lU/mL) of FII and FV in the load and in the elution fraction fresh, after 24h at ⁇ -65 2 C subjected to more than one freeze-thaw cycles and fresh fraction after 24h incubation at different temperatures (see Example 4B).
  • Fig. 6 is a bar graph showing the amount of FII and FV in the elution fraction after 24h at ⁇ -65°C subjected to more than one freeze-thaw cycles using different stabilizers, control samples do not include stabilizers.
  • Figs. 7A and 7B are bar graphs showing the stability of FII (Fig. 7A) and FV (Fig. 7B) in the elution fraction of an AEX column (Eshmuno Q) after dilution *4 with PuW, 20mM Citrate or 50mM Glycine buffers at pH 7.0-7.3, containing whether 1 or 5 mM CaCh. Untreated and diluted samples in different solutions were tested for FII and FV at Time 0 and after 24h incubation (from left to right in each quartet) at ⁇ -65°C, 2-8°C and room temperature (RT).
  • Fig. 8 is a graph showing the levels of FII and FV of the load and elution fraction of two different runs from an AEX column (Eshmuno Q), where A is the elution untreated, B is the elution diluted *4 with a buffer at pH 7.2 for a final concentration of ImM CaCh and llU/ml Heparin, and C is the elution diluted *4 with a buffer at pH 7.2 for a final concentration of ImM CaCh, llU/ml Heparin and 50 mM glycine.
  • A is the elution untreated
  • B is the elution diluted *4 with a buffer at pH 7.2 for a final concentration of ImM CaCh and llU/ml Heparin
  • C is the elution diluted *4 with a buffer at pH 7.2 for a final concentration of ImM CaCh, llU/ml Heparin and 50 mM glycine.
  • Figs. 9A to 9C show the effect of calcium ion on recovery
  • Figs. 9A and 9B are graphs showing the levels of FV (Fig. 9 A) and FIX (Fig. 9B) in the elution fraction from an AEX column (Eshmuno Q) after 24h incubation at ⁇ -65°C, 2-8°C and RT (from left to right), untreated and diluted *4 with 50mM glycine solution at pH 7.2 and 0. l-5mM CaCh, TO denotes Time 0; Fig.
  • 9C is a graph showing the recovery percent of FV in the elution fraction from an AEX column (Eshmuno Q) diluted *4 with 50mM glycine solution at pH 7.2 and 0.1-5mM CaCh after 24h incubation at 2-8°C..
  • Fig. 10 is a representation of the method used to lyophilize the elution fraction of an AEX (Eshmuno Q) concentrated 17 times from starting CDP material, showing the shelf temperature (solid line) and pressure (dashed line).
  • Blood clotting is a tightly controlled cascade, including a series of reactions in which among others, coagulation factors in zymogen form (inactive enzyme precursor) are activated, ultimately resulting in formation of a blood clot.
  • coagulation factors in zymogen form active enzyme precursor
  • formulations that comprise coagulation factors and specifically coagulation factors in zymogen form may play an important role in initiating and mediating blood clotting processes.
  • such formulations are not easily obtained nor maintained as stable formulations, due to, inter alia, degradation and activation of the zymogens.
  • the present disclosure is based on the development of purified, highly stabilized and ready to use formulations that comprise coagulation factors in an inactive, zymogen form.
  • a stabilizer such as a divalent cation
  • the inventors further found that the majority of these coagulation factors, some of which are known to be labile factors, may be maintained as zymogens in the formulation for at least 24 hours at about room temperature, specifically at a temperature of between about 18°C to about 26°C.
  • the presence of the stabilizer at specific concentrations does not promote the activation of the clotting cascade.
  • the formulation is administrated, for example by intravenous administration, the clotting cascade would be initiated, for example in case of trauma.
  • the present disclosure provides in accordance with some aspects, a formulation comprising concentrated Factor V, at least one vitamin K-dependent clotting protein and at least one stabilizer, wherein the at least one stabilizer is at a concentration at which the majority of Factor V and/or the at least one vitamin K-dependent clotting protein is present in the formulation in zymogen form.
  • the formulation in accordance with some embodiments of the present disclosure is to be understood as a hemostatic, blood clot-forming formulation, having ingredients that upon contact with blood at certain conditions (e.g. presence of specific factors at the bleeding site) react to subsequently form active components and thereby stop/arrest bleeding.
  • formulation ingredients do not interact with each other and are essentially inactive, i.e. present in a zymogen form, until they are brought into contact with blood at certain conditions, at which time clotting initiates and a blood clot is formed.
  • the formulation can be in any form.
  • the formulation is in a liquid form.
  • a liquid form it is to be understood as one being liquid at room temperature.
  • the formulation is solid e.g. in powder form or in lyophilized form. When in powder or lyophilized form, it is mixed with a suitable aqueous formulation such that upon use, the formulation is in liquid form.
  • the solid composition is stable.
  • stable means e.g. when one or more of the 5 factors keeps equal or more of about 70% of its activity when stored for one month at room temperature.
  • Reconstituted solid composition with an aqueous liquid is stable e.g. when one or more of the 5 factors keeps equal or more of about 70% of its activity when stored for about 12 hours at room temperature.
  • the formulation is in a frozen form.
  • the formulation is thawed upon use to be, at room temperature, in its liquid form.
  • the liquid carrier is typically a buffer to maintain the pH of the formulation at a pH value of between about 6.5 and about 8.5.
  • the pH is between about 6.5 and about 8.0, at times between about 6.5 and about 7.5, at times between about 7.0 and about 8.0, at times between about 7.0 and about 7.3, at times about 7.2.
  • the formulation comprises coagulation factors in a zymogen form.
  • a zymogen as used herein is to be understood as the inactive precursor form of the factor (enzyme), that required a biochemical change (such as a hydrolysis reaction revealing the active site or changing the confirmation to reveal the active site) in order to become an active factor (enzyme).
  • the coagulation factors are maintained/present in its majority in the formulation as zymogens, the formulation is not active, i.e. activation of components in the formulation is minimal or absent.
  • the presence of the clotting factors in a zymogen form can be determined by testing the activity of the formulation by using any known method in the field at different conditions (e.g. different time points and different temperatures). Such methods include, for example, chromogenic kits such as HYPHENTM or clotting kits such as STAGOTM . Chromogenic assays make use of a change in a color of a substrate when cleaved by the factor which is an enzyme and clotting assay uses the change in viscosity produced by the clotting of fibrinogen. For example, in clotting assays, the activity can be tested using activated partial thromboplastin clotting time (aPTT).
  • aPTT activated partial thromboplastin clotting time
  • the aPTT is an example of a blood coagulation test that measures how long it will take to the blood to form a clot.
  • aPTT typically uses deficient plasma of a specific factors (i.e. does not contain a specific factor) and normal plasma that contain all factors close to 1 lU/ml as the reference.
  • Lack of activation of the formulation described herein can be determined, for example, by using the non-activated partial thromboplastin time (NaPTT) method, using phospholipids and no activator (kaolin).
  • NaPTT non-activated partial thromboplastin time
  • the presence of zymogens (i.e. lack of activity) of Factor V and/or zymogens of at least one vitamin K-dependent clotting protein in the formulation is determined at a temperature of about 37°C.
  • the majority of Factor V and/or the at least one vitamin Independent clotting protein is present in a zymogen form in the formulation for at least 1 hour, at times at least 2 hours, at times at least 3 hours, at times at least 4 hours, at a temperature of at most about 30°C.
  • the majority of Factor V and/or the at least one vitamin Independent clotting protein is present in a zymogen form in the formulation for at least 1 hour, at times at least 2 hours, at times at least 3 hours, at times at least 4 hours, at a temperature of at least one of 0°C, 1°C, 2°C, 3°C, 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C,
  • the majority of Factor V and/or the at least one vitamin independent clotting protein is present in a zymogen form in the formulation at a temperature of at most about 30°C, at times at most 26°C, for at least 4 hours.
  • the majority of Factor V and/or the at least one vitamin independent clotting protein is present in a zymogen form in the formulation at room temperature for at least 4 hours.
  • a factor being in a zymogen form it should be understood as if the specific factor is at least partially in an inactive form, such that the amount/fraction of the active form (if present) is not sufficient to initiate the activation of the formulation to thereby form a blood clot.
  • a factor in the zymogen form includes a factor having 70% and above in inactive form.
  • activation would be initiated upon contact with injured or exposed tissue where the negatively charged phospholipids and collagen is abundant. Such a condition would activate the tissue factor(s) and initiate a full coagulation cascade. For example, upon administration into the blood circulation this treatment can stop exsanguination which is the loss of blood to a degree sufficient to cause death.
  • the formulation comprises at least 20% of Factor V (i.e. as a zymogen) and 80% in an activated form (i.e. as Factor Va), at times at least 50% as Factor V and 50% as Factor Va, at times at least 60% as Factor V and 40% as Factor Va, at times at least 70% as Factor V and 30% as Factor Va, at times at least 80% as Factor V and 20% as Factor Va, at times at least 90% as Factor V and 10% as Factor Va, at times at least 98%, or at least 99% as Factor V is a zymogen.
  • Factor Va activated form
  • At least 50%, at times at least 60%, at times at least 70%, at times at least 80%, at times at least 90%, at times at least 98%, or at least 99% of Factor V is a zymogen in the formulation when measured at room temperature, at times at a temperature below 23°C, for at least 4 hours, at times for at least 8 hours, at times for at least 12 hours, at times for at least 18 hours or for at least 24 hours.
  • between about 50% and about 100%, at times between about 80% and about 100%, at times between about 98% and about 100%, at times between about 80% and about 90% of Factor V is in the zymogen form in the formulation when measured at room temperature for at least 4 hours, at times for at least 8 hours, at times for at least 12 hours, at times for at least 18 hours, or for at least 24 hours.
  • At least 50% of the factor V is in zymogen form in the formulation when measured at room temperature for at least 24 hours.
  • the formulation comprises Factor V (“FV”) also known as proaccelerin which is a protein of approximately 330kDa produced in the liver.
  • Factor V circulates in plasma as a single-chain glycoprotein in a zymogen form having essentially no activity in the blood clotting cascade and needs to be first cleaved and activated to express procoagulant activity.
  • the activated Factor V is denoted in the art as Factor Va.
  • the formulation comprises at least one vitamin K-dependent coagulation protein.
  • Vitamin K is known to participant in synthesis of several proteins that mediate both coagulation and anticoagulation.
  • Vitamin K-dependent coagulation protein as used herein refers to a protein, typically synthesized in the liver that is being involved in the coagulation process.
  • the vitamin K-dependent coagulation protein is a procoagulation protein.
  • the vitamin K-dependent coagulation protein is an anticoagulation protein.
  • the at least one vitamin K-dependent coagulation protein is pro-coagulation protein comprising at least one of Factor II, Factor VII, Factor IX or Factor X.
  • Factor II also denoted as prothrombin (EC 3.4.21.5) refers to a protein of approximately 72 kDa, that on activation, is proteolytically cleaved to form thrombin, and in turn acts as a serine protease that converts fibrinogen to fibrin.
  • the activated form of Factor II is denoted Factor Ila.
  • Factor VII also denoted as proconvertin (EC 3.4.21.21) is activated to FVIIa by different proteases.
  • the activated form of Factor VII is denoted Factor Vila.
  • Factor IX also denoted a Christmas factor (EC 3.4.21.22) is a blood clotting factor, a zymogen of serine protease that upon activation, is converted into the active serine protease and, in the presence of Ca 2+ and membrane phospholipids, it forms the activated factor IX (IXa).
  • the activated form of Factor IX is denoted Factor IXa.
  • Factor X also denoted as Stuart-Prower factor, (EC 3.4.21.6) is a serine endopeptidase and requires vitamin K for its synthesis in the liver. Factor X is activated, by hydrolysis, into factor Xa.
  • the pro-coagulation protein comprises Factor II, Factor VII, Factor IX and Factor X.
  • the formulation comprises zymogens of Factor II, Factor VII, Factor IX and Factor X.
  • the formulation comprises zymogens of Factor V, Factor II, Factor VII, Factor IX and Factor X.
  • the amounts of the various zymogens in the formulation may vary.
  • the formulation comprises concentrated zymogens.
  • concentrated denotes that the amount of at least one of the zymogens in the formulation is at least 1 unit/ml of zymogen, at times at least 2 units/ml of zymogen.
  • concentrated refers to the concentration of one or more of Factor V, Factor II, Factor VII, Factor IX and Factor X being equal to or more than about 5 times its corresponding concentration in plasma.
  • the formulation comprises at least 1 lU/ml of at least one of Factor V, Factor II, Factor VII, Factor IX and Factor X. In some examples, the formulation comprises at least 1 lU/ml of Factor IX.
  • U denotes a coagulation factor unit, that is a unit of a physiological measurement of a coagulation factor in 1 ml of human normal plasma.
  • IU refers to International Unit of a coagulation factor which is a physiological measurement in a given sample as it compared to an adequate intentional standard, e.g., as determined by the clotting assay against an internal reference standard for potency concentration measurement that has been calibrated against, for example, the World Health Organization (WHO) Second International Standard for Thrombin, 01/580.
  • WHO World Health Organization
  • Factor V is present in the formulation at a concentration that is at least 20%, at least 30% of the concentration of the at least one vitamin K-dependent coagulation protein.
  • Factor V is present in the formulation at a concentration that is at least 20%, at least 30% of the concentration of at least one of Factor II, Factor VII, Factor IX or Factor X. In some embodiments, Factor V is present in the formulation at a concentration that is at least 20%, or at least 30% of the concentration of Factor II.
  • Factor V is present in the formulation at a concentration that is at least 20%, or at least 30% of the concentration of Factor VII.
  • Factor V is present in the formulation at a concentration that is at least 20%, or at least 30% of the concentration of Factor IX.
  • Factor V is present in the formulation at a concentration that is at least 20%, or at least 30% of the concentration of Factor X.
  • the formulation comprises at least one stabilizer.
  • the at least one stabilizer is present in the formulation at a concentration such that the formulation components are stable (i.e. minimally or not degraded) and/or inactive (i.e. in a zymogen form). In other words, the presence of the stabilizer prevents or reduces the degradation of the coagulation factors.
  • coagulation factors have a short half-life in plasma, for example 5h (FVII) or lOOh (FII), or 12-36h (FV).
  • FVII 5h
  • FII lOOh
  • FV 12-36h
  • the stability of the formulation is determined as % activity of Factor V using clotting and chromogenic as described herein during the storage, particularly when the formulation is in liquid form, after storage at a temperature of below room temperature for at least 24 hours. In some examples, the stability is measured at a temperature of between about 2°C and 8°C and/or at about room temperature after at least 24 hours storage.
  • the term stable refers to one or more of the 5 factors keeping equal or more of about 70% of its activity.
  • a stable formulation when referring to a stable formulation it is also to be understood as one that, upon use, has clotting time that is not affected or is minimally affected by its storage conditions. In other words, upon use, the formulation will clot at essentially the same time period irrespective of whether it was stored at room temperature or at lower temperatures, e.g. between 1°C to room temperature, or 2°C-8°C.
  • the stabilizer is present at a concentration below 5mM. In some other embodiments, the stabilizer is present at a concentration of between about 0. ImM and about 5mM. In some embodiments, the stabilizer is present at a concentration of between about O.lmM and about 3mM. In some embodiments, the stabilizer is present at a concentration of between about O.lmM and about 2mM, at times between about 0. ImM and about ImM, at times between about 0.5mM and about 3mM, at times between about 0.5mM and 2mM. In some embodiments, the stabilizer is present at a concentration of about ImM.
  • the stabilizer comprises at least one divalent cation.
  • divalent cation include magnesium, calcium.
  • the at least one stabilizer is calcium ions.
  • the calcium ions are free calcium ions.
  • the term free calcium ions refer to ionized and non-chelated calcium ions. It should be noted that the presence of a chelating agent may reduce the concentration of free calcium ions. The term free also applies to other divalent cations that are encompassed by the present disclosures as being non-chelated cations and hence free cations.
  • the fine balance between the chelator concentration and the calcium and the ratio of chelator to calcium should be one that allows for a free calcium at concentrations in the range of above O.lmM and up to below 5mM.
  • the formulation comprises free calcium ions at a concentration of at most about 5mM.
  • the formulation comprises free calcium ions at a concentration of between about O.lmM and about 5mM, at times between about O.lmM and less than 5mM, at times between about O.lmM and about 3mM, at times between about O.lmM and about 2mM, at times between about O.lmM and about ImM, at times between about 0.5mM and about 3mM, at times between about 0.5mM and 2mM.
  • the formulation comprises free calcium ions at a concentration of about O.lmM, at times of about 0.3mM, at times of about 0.5mM, at times of about 0.8mM, at times of about ImM, at times of about 1.3mM, at times of about 1.5mM, at times of about 1.8mM, at times of about 2mM, at times of about 2.5mM, at times of about 3mM, at times of about 3.5mM, about 4mM, or about 4.5mM.
  • the formulation may also comprise an anti-coagulant protein.
  • the anticoagulant protein is in a zymogen form, i.e. an inactive anticoagulant protein.
  • the anti-coagulant protein is a vitamin K-dependent anticoagulation protein.
  • the anti-coagulant protein is a nonvitamin K-dependent anticoagulation protein.
  • the anti-coagulant protein is at least one of protein C, protein S or protein Z.
  • the anti-coagulant protein is at least one of protein C or protein S.
  • the anti-coagulant protein is anti-thrombin III (AT III).
  • the anti-coagulant protein is at least one of protein C, protein S or AT III.
  • the formulation may comprise additional components.
  • the formulation comprises at least one excipient.
  • the at least one excipient is at least one sugar.
  • the at least one excipient is at least one of mannitol, maltose, sucrose, glycerol, citrate or glycine.
  • the at least one excipient is glycine. It was suggested that glycine may be added to the formulation as it is suitable as a non-chelating (unlike e.g. citrate which has chelating activity) buffer hence, keeping calcium ions in a free non-chelated form, i.e. free calcium ions.
  • the coagulation factors as described herein including for example, Factor V, at least one vitamin K-dependent coagulation protein and the anti-coagulant protein, can be isolated from blood or plasma of human beings or mammals or can be recombinant factor(s).
  • the coagulation factors as described herein are derived from blood, plasma or any product/fraction thereof.
  • Blood, plasma or any product/fraction thereof as used herein refers to at least one of whole blood, fresh frozen plasma (FFP), platelet rich plasma (PRP), cryo-depleted plasma (CDP), cryo-precipitated plasma, recovered plasma, or source plasma obtained from plasma apheresis.
  • FFP fresh frozen plasma
  • PRP platelet rich plasma
  • CDP cryo-depleted plasma
  • cryo-precipitated plasma recovered plasma, or source plasma obtained from plasma apheresis.
  • FFP Free frozen plasma
  • Plate rich plasma is a concentrate of platelet-rich plasma protein derived from whole blood and centrifuged to remove red blood cells.
  • “Cryo-depleted plasma” as used herein relates to a component made from FFP, that remains once cryoprecipitate has been removed from FFP. CDP includes most of the clotting factors.
  • Cryoprecipitate as used herein, relates to precipitated proteins of plasma obtained from a single unit of fresh plasma and rapid thawing. Cryoprecipitate is rich in Factor VIII, factor XIII, von Willebrand factor and fibrinogen.
  • Recovered plasma as used herein, relates a fraction collected through whole blood donation and being separated from its cellular components.
  • Apheresis refers to blood of a person that passes through an apparatus that separates out one particular constituent and returns the remainder to the circulation.
  • the coagulation factors are derived from CDP.
  • Factor V is derived from CDP.
  • the at least one vitamin K-dependent coagulation protein is derived from CDP.
  • Factor II, Factor VII, Factor IX and Factor X are derived from CDP.
  • the at least one anti-coagulant protein is derived from CDP.
  • at least one of protein C, protein S or AT III is derived from CDP.
  • the formulation described herein is suitable for systemic administration.
  • Systemic administration as used herein mean that the administration of a formulation directly intravenously into the central blood system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes.
  • parenteral administration as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, intravenous injection or intraarterial.
  • the formulation is suitable for intravenous injection. In some embodiments, the formulation is suitable for intravenous infusion.
  • the formulation may be used for the treatment of a variety of disorders associated with bleeding such as various coagulation abnormalities as well as spontaneous bleeding episodes, trauma and in surgical procedures.
  • the present disclosure provides in accordance with some other aspects, a method for the treatment, inhibition, arresting or delaying bleeding or any disorder associated thereto.
  • the methods of the invention comprise a step of administering to a subject in need thereof an effective amount of the formulation described herein.
  • the methods of the invention employ administering to a bleeding subject a therapeutically effective amount of a formulation of the invention.
  • the methods comprise administering to a subject in need thereof an effective amount of the formulation comprising Factor V, at least one vitamin K-dependent clotting protein and at least one stabilizer, wherein the at least one stabilizer is present in the formulation at a concentration at which the Factor V and the at least one vitamin K-dependent clotting protein are zymogenes.
  • the methods of the invention comprise administering to a subject in need thereof an effective amount of the formulation comprising Factor V, at least one vitamin K-dependent clotting protein and at least one stabilizer at a concertation of below about 5mM, at times between about 0. ImM and about 5mM, at times about 2mM.
  • the methods of the invention comprise administering to a subject in need thereof an effective amount of the formulation comprising Factor V, at least one vitamin K-dependent clotting protein and free calcium ions at a concertation of below about 5mM, at times between about O.lmM and about 5mM, at times about 2mM.
  • the methods of the invention comprise administering to a subject in need thereof an effective amount of the formulation comprising Factor V, at least one of Factor II, Factor VII, Factor IX and Factor X and free calcium ions at a concertation of below about 5mM, at times between about O.lmM and about 5mM, at times about 2mM.
  • the methods of the invention comprise administering to a subject in need thereof an effective amount of the formulation comprising Factor V, at least one vitamin K-dependent clotting protein, a stabilizer and at least one anti-coagulation protein as described herein.
  • the methods of the invention comprise administering to a subject in need thereof an effective amount of the formulation comprising Factor V, at least one of vitamin K-dependent clotting protein, a stabilizer and at least one anti-coagulation protein as described herein.
  • the anti-coagulation protein in some examples is at least one of protein C, protein S or AT III.
  • the methods of the invention comprise administration of the formulation of the invention that is derived from at least one of whole blood, fresh frozen plasma (FFP), platelet rich plasma (PRP), cryo-depleted plasma (CDP), cryo-precipitated plasma, recovered plasma, or source plasma obtained from plasma apheresis.
  • FFP fresh frozen plasma
  • PRP platelet rich plasma
  • CDP cryo-depleted plasma
  • cryo-precipitated plasma recovered plasma
  • recovered plasma or source plasma obtained from plasma apheresis.
  • the methods of the invention comprise administration of the formulation that is derived from CDP.
  • the formulation of the invention comprises zymogens and hence the formulation is not active prior to its administration.
  • the formulation is activated after being administered into the subject by the methods described herein.
  • the formulation of the invention is to be administered, as detailed herein, to a subject suffering from bleeding or any disorder associated thereto, such that upon administration as detailed herein, the zymogens may be eventually activated by upstream clotting factors in the normal flow of the clotting cascade.
  • bleeding or bleeding disorder refers to at least one defect in hemostasis resulting in an increased susceptibility to bleeding (also known as hemorrhagic diathesis).
  • the bleeding in accordance with some embodiment is associated with hemostatic disorders.
  • the method of the invention may be applicable for reversing exsanguination.
  • Exsanguination refers to loss of blood to a degree sufficient to cause death.
  • the method of the invention may be applicable for the treatment, prevention, arresting, prophylaxis, amelioration, inhibition of bleeding, hemostatic disorders and any bleeding or disorder associated therewith in a subject in need thereof, the method comprising the step of administering to said subject a therapeutically effective amount of the formulation of the invention.
  • Bleeding disorders can be caused by various physiological processes.
  • bleeding disorders may be caused by platelet disorders (primary hemostasis defect), coagulation defects (secondary hemostasis defect), or a combination thereof.
  • Platelet disorders are typically associated with mucocutaneous bleeding (e.g., epistaxis, petechiae, gastrointestinal bleeding) whereas coagulation defects are typically associated with bleeding into potential spaces (e.g., hemarthrosis, muscular bleeding).
  • the methods of the invention may be applicable for subjects suffering from a bleeding disorder that may be an inherited or acquired bleeding disorder.
  • the methods of the invention may be applicable for subjects suffering from acquired bleeding disorders.
  • Acquired bleeding disorders are caused by an external stimulus.
  • the acquired bleeding disorder may be at least one of injury-induced bleeding, surgery -induced bleeding or trauma-induced bleeding.
  • the method of the invention may be applicable for treating, inhibiting, arresting or delaying bleeding associated with surgical procedures.
  • the method of the invention is suitable for treating trauma- induced bleeding.
  • the methods of the invention may be applicable for subjects suffering from a trauma, for example from trauma induced coagulopathy.
  • the methods of the invention may be applicable for subjects suffering from a bleeding disorder that may be an inherent bleeding disorder. "Inherent bleeding disorder" as used herein relates to an inherent deficiency in at least one coagulation factor.
  • the methods of the invention may be applicable for subjects suffering from at least one of Factor I deficiency, Factor II deficiency, Factor V deficiency, Factor VII deficiency, Factor VIII deficiency (also known as hemophilia A), Factor IX deficiency (also known as hemophilia B), Factor X deficiency, Factor XI deficiency, Factor XII deficiency or Von Willebrand disease (VWD).
  • Factor I deficiency also known as hemophilia A
  • Factor IX deficiency also known as hemophilia B
  • Factor X deficiency also known as hemophilia B
  • Factor X deficiency also known as hemophilia A
  • Factor XI deficiency also known as hemophilia B
  • VWD Von Willebrand disease
  • the invention may be particularly applicable for treating, inhibiting, arresting or delaying bleeding associated with factor V deficiency.
  • the method of the invention may be applicable for treating, inhibiting, arresting or delaying bleeding associated with factor XI deficiency.
  • the method of the invention may be applicable for treating, inhibiting, arresting or delaying bleeding associated with factor VII deficiency.
  • the method of the invention may be applicable for treating, inhibiting, arresting or delaying bleeding associated with factor X deficiency.
  • the methods of the invention may be applicable for treating, inhibiting, arresting or delaying bleeding associated with factor II deficiency.
  • disease As used herein, “disease”, “disorder”, “condition” and the like, as they relate to a subject's health, are used interchangeably and have meanings ascribed to each and all of such terms. It is understood that the interchangeably used terms "associated” and “related”, when referring to pathologies herein, mean diseases, disorders, conditions, or any pathologies which at least one of: share causalities, co-exist at a higher than coincidental frequency, or where at least one disease, disorder, condition or pathology causes a second disease, disorder, condition or pathology.
  • the invention provides methods for treating disorders specified above.
  • treatment refers to the administering of a therapeutic amount of the formulation of the present invention which is effective to improve or avoid one or more undesired symptoms associated with a disease or condition as described herein.
  • the method of the invention involves the administration of a therapeutically effective amount of the combinations of the invention.
  • effective amount or “therapeutically effective” for purposes disclosed herein indicates that the amount of formulation is effective to treat, inhibit or delay one or more symptoms of a disease as described herein.
  • the term “subject” refers to a living organism that is treated with the formulation as described herein, including, but not limited to, any mammal, such as a human.
  • the methods of the invention are not limited to any route of administration.
  • the formulations may be administered systemically.
  • the method comprises systemic administration of the formulations of the invention.
  • method comprises injection or infusion of the formulations.
  • the present disclosure provides in accordance with some other aspects, a formulation for use in the treatment, inhibition, arresting or delaying bleeding or any disorder associated thereto.
  • the formulations of the invention may be relevant for the treatment of bleeding in a subject in need thereof, wherein the formulations comprise Factor V, at least one vitamin K-dependent clotting protein and at least one stabilizer, wherein the at least one stabilizer is present in the formulation at a concentration at which the Factor V and the at least one vitamin K-dependent clotting proteins are zymogenes.
  • the formulation of the invention is applicable for systemic use.
  • kits may comprise a formulation comprising concentrated Factor V, at least one vitamin K- dependent clotting protein and at least one stabilizer at a concertation of below about 5mM, at times between about O.lmM and about 5mM, at times about 2mM.
  • the kit of the invention is for use in a subject suffering from bleeding or any disorder associated thereto as described herein above. It should be further appreciated that the kit of the invention may be also used for preventing bleeding in subjects having an increased risk for bleeding. In some embodiments, the kit further comprises instructions for use of the formulation to treat, inhibit or delay bleeding or any disorder associated thereto.
  • the instructions comprise administrating the formulation in liquid form.
  • the kit of the invention may be particularly suitable for systemic use.
  • the instructions comprise administrating the formulation by systemic administration.
  • the kit may further include container means for containing the formulation.
  • the kit comprises an applicator configured to allow administration of the formulation, preferably by systemic administration such as infusion or injection.
  • the kit comprises the formulation within an applicator.
  • the applicator is a syringe.
  • a further aspect of the invention relates to a process for the preparation of the formulation.
  • the process of the invention comprises the step of subjecting blood or plasma as described herein to at least one separation step followed by recovering the formulation of the invention.
  • the present disclosure provides a process for the preparation of a formulation comprising concentrated Factor V and at least one vitamin K-dependent clotting protein in zymogen form.
  • the process may comprise the step of subjecting at least one of whole blood, fresh frozen plasma (FFP), platelet rich plasma (PRP), cryo-depleted plasma (CDP), cryoprecipitated plasma, recovered plasma, or source plasma obtained from plasma apheresis to at least one separation step.
  • FFP fresh frozen plasma
  • PRP platelet rich plasma
  • CDP cryo-depleted plasma
  • cryoprecipitated plasma recovered plasma, or source plasma obtained from plasma apheresis
  • the at least one separation step as used herein refers to any method known in the art for separating substances from blood, plasma or any product/fraction thereof as described herein.
  • the process may comprise use of a surface of a solid phase capable of binding at least a portion of the plasma/blood components and hence separating plasma/blood components from each other.
  • the at least one separation step may comprise a chromatography method, a centrifugation method or any combination thereof.
  • the at least one separation step may comprise a chromatography method by column or batch, a centrifugation method, salting out or saturation with heparin, PEG or ammonium sulfate precipitation or any combination thereof.
  • the separation step comprises a chromatographic step.
  • the chromatographic step comprises at least one of a column chromatography, an ion-exchange chromatography, a gel-permeation chromatography, an affinity chromatography, a size-exclusion chromatography, or a hydrophobic interaction chromatography.
  • the separation may be done by a column setup, a batch setup or any combination thereof such as a hybrid setup.
  • a column setup a solid medium is packed onto a column, and the mixture such as, plasma, is allowed to move through the column to allow settling, a wash buffer run through the column and the elution buffer subsequently applied to the column and collected.
  • a batch set up includes the following: adding the initial mixture, for example a plasma sample to the solid phase in a vessel, mixing, separating the solid phase, removing the liquid phase, washing, re-centrifuging, adding the elution buffer, recentrifuging and removing the elute.
  • the chromatographic step comprises an ion exchange chromatography.
  • This chromatography method is based on electrostatic interactions between charged protein groups, and solid support material (matrix).
  • Ion exchange chromatography includes anion-exchange chromatography and cation-exchange chromatography, with the former using positively charged resins while adsorbing negatively charged components and the latter vice versa.
  • the chromatographic step comprises at least one anion exchange chromatography step.
  • the process comprises subjecting at least one of whole blood, FFP, PRP, CDP, cryo-precipitated plasma, recovered plasma, or source plasma obtained from plasma apheresis to at least one chromatography step and specifically to at least one anion exchange chromatography step and collecting an eluent into a solution comprising a stabilizer.
  • the process comprises subjecting at least one of whole blood, FFP, PRP, CDP, cryo-precipitated plasma, recovered plasma, or source plasma obtained from plasma apheresis to at least one chromatography step and specifically to at least one anion exchange chromatography step and transferring an eluent into a solution comprising a stabilizer.
  • the stabilizer is present in the collection solution at a concentration such that the coagulation factors recovered by the process of the invention are at a zymogen form.
  • the collection solution (denoted herein at times also as the formulation of the invention) comprises at least one stabilizer at a concentration of at most about 5mM.
  • the eluent is immediately transferred to a storage solution comprising at least one stabilizer at a concentration of at most about 5mM.
  • the storage solution in accordance with such embodiments is referred to herein as the formulation of the invention.
  • the process comprises subjecting CDP to at least one anion exchange chromatography step and collecting the eluent into a formulation comprising a divalent cation such as calcium ions.
  • the process comprises collecting the eluent into a formulation comprising free calcium ions at a concentration of below about 5mM. In some examples, the process comprises collecting the eluent into a formulation comprising free calcium ions at a concentration of between about 0. ImM and below about 5mM, at times between about O.lmM and about 3mM, at times between about O.lmM and about 2mM, at times between about O.lmM and about ImM, at times between about 0.5mM and about 3mM, at times between about 0.5mM and 2mM. In some embodiments, the process comprises collecting the eluent into a formulation comprising calcium ions at a concentration of about 0.
  • ImM at times of about 0.3mM, at times of about 0.5mM, at times of about 0.8mM, at times of about ImM, at times of about 1.3mM, at times of about 1.5mM, at times of about 1.8mM, at times of about 2mM, at times of about 2.5mM, at times of about 3mM, at times of about 3.5mM or about 4mM.
  • the elution solution comprises glycine. In some other embodiments, the elution solution comprises sodium chloride. In some other embodiments, the elution solution has a pH of between about 6.0 and about 10.0.
  • the collection solution has a pH of between about 6.0 and about 10.0, at times between about 6.5 and about 9, at times between about 6.8 and about 8.5, at times between about 6.8 and about 8.0, at times between about 7.0 and about 8.0.
  • the process of the invention may comprise additional steps.
  • the process comprises a step of washing a fraction bound to the ion exchange with a washing solution prior to eluting the bound fraction with an elution solution into the collection solution.
  • the present disclosure also provides a formulation obtainable by the process of the present disclosure.
  • These assays determined specific procoagulants concentration of both the extrinsic and the intrinsic pathways by measuring clotting time of tested sample and using specific relevant deficient plasma.
  • the clotting time is measured using the STart®4 (Stago) clotting machine according to the manufacturer instructions.
  • procoagulants concentration was performed according to the manufacturer’s instructions (Stago Start-4 SOP ref 26987).
  • the principle of the test consists of the use of calcium thromboplastin (tissue factor) to measure the clotting time of the tested sample and to compare with that of the normal standard (Uni-calibrator Cat. #00625).
  • Specific factors concentration is determined using the relevant specific deficient plasma (i.e. deficient factor II and deficient factor V).
  • the deficient plasma supplies all the factors in excess except for the factor being tested which is supplied by the tested sample.
  • the concentration of the tested factor (%) is interpolated from the calibration curve which was prepared by diluting the Unicalibrator in Owren-Koller buffer (Cat.
  • the determination of the intrinsic pathway procoagulant concentration was performed according to the manufacturer’s instructions (Stago Start-4 SOP ref 26987) using C.K. PREST® kit (Cat. #00847).
  • the test involves the recalcification of plasma in the presence of a standardized amount of cephalin (Platelet substitute) and a specific activator. This procedure minimizes test variables by standardizing the contact activation and by optimizing the concentration of the platelet like phospholipids.
  • the clotting time of the tested sample is measured and compared with that of the normal standard (Unicalibrator Cat. #00625).
  • Specific factor’s concentration is determined using the relevant specific deficient plasma (i.e. deficient IX). The rest of the assay was performed as described above for the common pathway factors.
  • Procoagulant inhibitor concentration was performed according to the manufacturer’s instructions (Stago Start-4 SOP ref 26987) using Staclot® Protein S kit (Cat. #00746).
  • the principle of the assay is based upon the cofactor activity of Protein S which enhances the anticoagulant action of activated Protein C. This enhancement is reflected by the prolongation of the clotting time of a system enriched with factor Va which is a physiological substrate for activated protein C.
  • the assay was performed as described above for the common pathway factors. Determination of Procoagulants Concentration in Tested Samples using Chromogenic Assay
  • These assays determined specific procoagulants concentration of FVII, FX, Protein C and Antithrombin III by using chromogenic method according to the EU Pharmacopeia. The OD is measured using an ELISA reader.
  • Factor VII The determination of Factor VII was performed according to the manufacturer’s instructions (Hyphen Biomed) using BIOPHEN FVII kit (Cat. # 221304).
  • tissue factor rabbit thromboplastin
  • factor FVII forms an enzymatic complex which activates the factor X, present at a constant concentration and in excess, to factor Xa.
  • the amount of factor Xa formed depends on the concentration of Factor VII to be assayed.
  • This factor Xa formed cleaves the specific substrate Xa (SXa-11) and releases para- nitroaniline (pNA).
  • the amount of pNA generated is directly proportional to the Factor Xa activity.
  • the amount of Factor VII in the assayed sample is directly proportional to the Factor Xa activity generated, measured by the amount of pNA released, determined by color development at 405 nm.
  • Factor X The determination of Factor X was performed according to the manufacturer’s instructions (Hyphen Biomed) using BIOPHEN FX kit (Cat. # 221705). Using the BIOPHEN Factor X assay, Factor X is measured following a specific activation with RVV, an enzyme extracted from snake venom (Russell’s viper venom). Activated Factor X (FXa) then specifically cleaves the specific substrate SXa-11, releasing paranitroaniline (pNA), which color is measured at 405nm. There is a direct relationship between color development and Factor X activity in the tested plasma.
  • Protein C was determined according to the manufacturer’s instructions (Hyphen Biomed) using BIOPHENTM Protein C (LRT) (Cat. # 221211- RUO). Using this assay, Protein C is measured following a specific activation with Protaca, an enzyme extracted from snake venom (Agkistrodom C Contortrix). Activated protein C (APC) then specifically cleaves the specific substrate SaPC-21, releasing para- nitroaniline (pNA), which color is measured at 405nm. There is a direct relationship between color development and Protein C activity in the tested plasma.
  • BIOPHENTM Antithrombin assay is a kinetic method based on the inhibition of FXa, which is at a constant concentration and in excess, by AT in presence of heparin. The remaining FXa is then measured by its amydolitic activity on a FXa specific chromogenic substrate, which releases pNA. The amount of pNA generated is inversely proportional to the AT concentration present in the tested plasma. The assay is insensitive to heparin.
  • the BIOPHENTM ANTI-Xa (2 Stages Heparin Assay) assay is a method based on the inhibition of a constant amount of Factor Xa (FXa), by the tested heparin in presence of exogenous antithrombin (stage 1), and hydrolysis of a Factor Xa specific chromogenic substrate (CS 11(65)), by the Factor Xa in excess (stage 2).
  • FXa Factor Xa
  • CS 11(65) Factor Xa specific chromogenic substrate
  • pNA is then released from the substrate.
  • the amount of pNA released (measured at 405 nm) is then a relation of the residual Factor Xa activity. There is an inverse relationship between the concentration of heparin and color development.
  • the resins two strong and two weak anion exchange resins as detailed in Table 1, were tested at different pH values: 7.0, 7.5, 8.0 and 8.5.
  • Cryo-Depleted Plasma (CDP) produced at Omrix (Plasma Fractionation Institute, Tel-Hashomer, Israel) was used as the starting material for the screening process. Protein Concentration: >47 mg/ml protein.
  • CDP batch # X22Y730 was thawed, filtered with 0.8/0.2 pm PES filter and aliquoted. The aliquots were pH adjusted to 4 different pH values: 7.0, 7.5, 8.0 or 8.5. Then, the aliquots were frozen again and thawed before each assay.
  • the resins were washed with 3CV's (column volume) of Purified water (PuW) and 3CV's of IM NaCl. These steps were carried out by rolling 5min at room temperature (RT) and then left standing until full decantation was obtained.
  • 3CV's column volume
  • Purified water Purified water
  • IM NaCl IM NaCl
  • 150pl (which is consider as 1CV) of each of the resins were used for the experiment. Each process was executed in duplicates and the samples generated in each step were combined before testing. During the Load, Wash and Elution steps shown in Table 2A, the resins were incubated with the sample/buffers at each of 4 different pH values (7.0, 7.5, 8.0 and pH 8.5). Each tested resin was subjected to 1 min rolling, then centrifuged for 1 minute at 500g, and then the supernatant was collected, except of the equilibration step which was discarded.
  • Samples were taken from the supernatant after the centrifugation step, from Unbound ( ⁇ 1.8ml each), Wash ( ⁇ 2ml) and Elutions 1 and 2 ( ⁇ 0.6ml each). The duplicates were combined into one sample, and then aliquoted into 4 aliquots and stored at ⁇ -65°C for testing.
  • Cryo Depleted Plasma produced at Omrix (Plasma Fractionation Institute, Tel-Hashomer, Israel) was used as the starting material for the screening process.
  • Protein Concentration >47 mg/ml protein.
  • CDP batch # X22Y730 was thawed, supplemented with llU/ml Heparin, filtered with 0.8/0.2 pm PES filter and aliquoted. The aliquots were pH adjusted to two different pH values: 7.0 and 8.0. Then, the aliquots were frozen again and thawed before each assay.
  • Equilibration buffer 10 mM citrate, pH adjusted to 7.0 and 8.0.
  • Elution Buffer lOmM Sodium citrate, IM NaCl, pH 8.0.
  • 0.5ml (which is consider as 1CV) of each of the resins were used for the experiment. Each process was executed in duplicates and the samples generated in each step were combined before testing. The screening was carried out in two different pH values (7.0 and 8.0). For steps 1-3 (see Table 2B), the incubation was carried out for 1 minute and then the sample was left standing until complete decantation of the resin was obtained. During the Load, Wash and Elution (steps 4-6) the sample/buffers were incubated for 1 min while rolling and then centrifuged for 1 minute at 500g and the supernatant was collected.
  • Fig. 1 shows the levels of procoagulants and inhibitors in the elution fraction for each of the different resins studied in Units of activity per ml of load at pH 8.0.
  • the levels of FIT, FVII, FIX and FX are overall satisfactory however, FV is present in very low levels ( ⁇ 0.10IU/ml), from which an important part did not bind to the resins (present in the UB fraction) and another part may have been degraded during the purification process.
  • CDP loading material
  • llU/ml Heparin was spiked with llU/ml Heparin, filtered through a PES 0.2pm filter and then adjusted to pH 8.0 (pH 7.0 for C67 and C68).
  • pH 8.0 pH 7.0 for C67 and C68.
  • Regeneration method 150cm/h: IM NaCl 3CV, 0.5M HC1 2CV, PuW 2CV, 0.5M NaOH 2CV, NaOH incubation 60min, IM NaCl 3CV, PuW 2CV, 20-25% Ethanol 2CV.
  • the hardware used was Tricorn 10x200mm for Fractogel TMAE (M), Gigacap DEAE, Capto DEAE and Unosphere Q and Hi Scale 26 for Eshmuno Q.
  • Fig. 2 shows the activity of FIT, FV and FIX in the elution fraction of 5 different packed resins.
  • Fractogel TMAE has shown very high levels with 57% (15CV) and 88% (17CV) of FV. In all other runs, FV ranged between 30-35%. Finally, FIX was found in high levels in at least one of the runs for each resin, except for Capto DEAE, where only 14% were detected. The highest value was observed using Eshmuno Q.
  • the aim of this experiment was to analyze of the effect of the pH, flowrate and temperature on the performance of one of the tested resins.
  • the Eshmuno Q column was used as an exemplary resin in the purification of the full set of proteins for a formulation from CDP.
  • the experiments were conducted with Eshmuno Q, using a prepacked column with dimensions 8x100mm (5ml CV). Three variables were selected for this aim: chromatography temperature, pH of equilibration buffer and load, and the linear velocity of the loading step. Eight runs were carried out combining extreme values:
  • the 3CV elution ( ⁇ 15ml) was collected into 45ml of a solution containing CaCh, Glycine and Heparin at pH 7.2, targeting for a final concentration of ImM CaCh, 50mM Glycine and llU/ml Heparin.
  • Coagulation factors in the plasma are known to have a half-life between 5h (FVII) to lOOh (FII), however, in the elution fraction of the AEX chromatographic column, the stability is reduced significantly, especially that of FV, which presents a challenge for the purification process. Further, Calcium, Mannitol, Maltose, Sucrose, Glycerol, and Glycine were tested when incubating at different temperatures for 24h, and after freezethaw cycles at ⁇ -65°C. In addition, the optimal pH was analyzed in this study.
  • the following experiment was aimed to determine the effect of the pH in a range of 6.7-7.7 in order to determine the optimal pH for the stability of FII and FV.
  • the elution fraction of a chromatographic run in an Eshmuno Q 2ml column was used for the experiment, where 25ml of CDP (batch #X33Y 140) were loaded into the column and the elution fraction was stored at ⁇ -65°C.
  • the elution sample was then thawed and adjusted to three different pH values A) 6.7, B) 7.2 and C) 7.7. Each sample was aliquoted and incubated overnight (24h) in two different temperatures: Al, Bl, Cl at RT, and A2, B2, C2 at 2-8°C.
  • an untreated control was stored at ⁇ -65°C during the 24h.
  • FII and FV levels are shown in Fig. 4A and 4B, respectively.
  • FII in the control was 0.77 lU/ml.
  • the sample at pH 6.7 showed a similar value to that of the control, while increasing the pH seemed to improve the stability, reaching 0.97 and 1.15 lU/ml respectively for pH 7.2 and 7.7.
  • no clear trend was found throughout the pH range, with values of 0.90, 0.77 and 0.85 lU/ml respectively at pH 6.7, 7.2 and 7.7.
  • Fig. 4A FII in the control was 0.77 lU/ml.
  • the sample at pH 6.7 showed a similar value to that of the control, while increasing the pH seemed to improve the stability, reaching 0.97 and 1.15 lU/ml respectively for pH 7.2 and 7.7.
  • no clear trend was found throughout the pH range, with values of 0.90, 0.77 and 0.85 lU/ml respectively at pH 6.7, 7.2 and 7.7.
  • the aim of this study is to determine how the stability of an elution sample obtained from an AEX column is affected by the storage temperature.
  • Fig. 5 shows results of this study.
  • the levels of FII and FV in the fresh condition and after 24h at three different temperatures: ⁇ -65°C, 2-8°C and Room Temperature (RT) were analyzed, including the effect of 2 cycles of freeze-thaw at ⁇ -65°C.
  • a chromatographic run (C65R2) was carried out using Fractogel TMAE (M) Medcap prepacked 1 ml column at pH 8.0.
  • CDP (batch #X33Y140). Loading material was spiked with HU/ml Heparin, filtered through a PES 0.2pm Supor filter and pH was adjusted to 8.0. 32.5 ml were loaded into the column and the bound material was eluted with a IM NaCl + 20mM Sodium citrate buffer. The 3.5CV of elution collected were diluted 1/5 with a buffer at pH 7.2 containing a concentration of 20mM Sodium Citrate, ImM CaCh. In this eluted sample, the concentration factor (volume of Load / volume of Elution) was 1.7. This elution was tested for FII and FV fresh and after 24h at different temperatures:
  • the load presented 1.06IU/ml FII, from which 0.56IU/ml were recovered in the fresh elution.
  • 0.64 and 0.69IU/ml FII were obtained, slightly higher than the fresh sample.
  • the 24h freeze-thaw cycles presented 0.64 and 0.55IU/ml consecutively, showing a trend of degradation equivalent to 0. llU/ml decrease per cycle.
  • 0.76IU/ml FV were obtained in the load, from which only O.33IU/ml were recovered, representing less than half of the activity.
  • Samples incubated 24h at 2-8°C and RT presented an almost complete degradation with 0.12 and O.lOIU/ml FV respectively.
  • Example 4C The effect of freeze-thaw cycles on the FII and FV levels using sugars at 10%
  • the aim of this study was to study the effect of different sugars on the stability of FII and FV in an elution sample obtained from an AEX column, after two Freeze-thaw cycles at ⁇ -65°C.
  • the elution fraction was tested for FII and FV fresh and after cycles of 24h Freeze-Thaw with and without 10% sugars.
  • the aim of this experiment is to study the effect of diluting the elution fraction obtained from an AEX column with PuW, Citrate and Glycine buffers, containing small amounts of CaCh inside the range of pH 7.0-7.3 as potential stabilizer for FV. Samples untreated and diluted in different solutions were tested for FII and FV at T-0 and after 24h incubation at ⁇ -65°C, 2-8°C and RT.
  • CDP loading material was spiked with HU/ml Heparin, filtered through a PES 0.2pm Supor filter and pH was adjusted to 7.9.
  • 75 ml of CDP (batch #X33Y 140) were loaded into the column and 86ml of UB were collected (which includes 2CV of the flush).
  • the bound material was eluted with a IM NaCl + 20mM Sodium citrate buffer, and then the volume was divided into 7 samples:
  • the starting material presented 1.14 lU/ml FII and 0.80 lU/ml FV.
  • Untreated samples of FII should contain the same composition of the buffer in which it was eluted, which is 20mM Citrate + 5 mM CaCh.
  • pH 8.0 A
  • the samples presented very similar values when incubated at 24h at different temperatures (values between 0.90-0.97IU/ml) compared to T-0 (0.96IU/ml).
  • Adjusting the pH to 7.2 B
  • FII seems to be stable after 24h across all conditions and incubation temperatures, without evidencing any benefit by diluting *4 with PuW (C and D), Citrate (E and F) or Glycine (G). All values after 24h incubation ranged between 0.80 to 0.95 lU/ml, representing recoveries between 0.70 to 0.83% (Fig. 7A).
  • Treated samples showed a different pattern: an increase in the stability seems to occur for all dilutions at T-0 when compared to the untreated (A and B), with associated values of 0.70 (C), 0.78 (D), 0.53 (E), 0.73 (F) and 0.85IU/ml (G), representing >88% recoveries to that of the load (0.80IU/ml), being G the best result (50mM Glycine, ImM Calcium).
  • Example 6 Dilution ( with a buffer at pH 7.2 containing Calcium
  • experiment C63R4 showed a similar trend, with a starting material at 0.68IU/ml, an elution at 0.26IU/ml when untreated (A), while 0.46IU/ml were obtained when diluting *4 in calcium buffer.
  • the aim of this experiment was to determine the range in which calcium serves as a stabilizer of coagulation factors V and IX in the elution fraction without provoking activation.
  • a suitable amount of CDP (batch #W35Y440) containing HU/ml Heparin was filtered through a PES 0.2pm Supor filter and pH was adjusted to 7.2. 20ml were loaded into a 1ml Eshmuno Q column, where 21ml of UB were collected, and the bound proteins were eluted with 3ml (3CV) of a buffer containing IM NaCl and 50mM Glycine at pH 7.2.
  • the elution sample was divided into 6 aliquots, from which one sample was kept untreated (A) and 5 of them were diluted 1/4 with 50mM glycine solution at pH 7.2 containing different concentrations of CaCh to obtain a final concentration of: B) 0. ImM, C) 0.5 mM, D) 1.0 mM, E) 2.0 mM and F) 5.0mM.
  • FV and FIX was determined in all samples just after treatment (To), and after 24h incubation at ⁇ -65°C (freeze-thaw), 2-8°C and at room temperature (RT).
  • FIX activity was affected as well in untreated samples after 24h incubation, passing from 0.96IU/ml in the load to 0.83, 0.72 and 0.74IU/ml respectively at ⁇ -65°C, 2-8°C and RT.
  • the presence of calcium between 0.1-2.0mM stabilized the activity of FIX in all conditions, while, as mentioned above, the addition of 5mM provoked the activation of the cascade, evidenced by an immediate clotting after addition of 25mM calcium (FV and FIX deficient clotting assay).
  • FV and FIX deficient clotting assay As shown in Fig.
  • FII may be stable in a wide range of conditions.
  • FV is highly unstable during its purification from plasma using AEX, experiencing immediate degradation from the moment it elutes from the column and probably even during the run itself (higher flowrates show higher recoveries for FV).
  • one effective way to stabilize coagulation factors during the production of a formulation is the use of a buffer at pH 7.2 containing ImM calcium.
  • the buffer may also comprise Glycine as a good option for a parenteral drug production process, and heparin to keep pro-coagulants inactive.
  • Glycine a good option for a parenteral drug production process
  • heparin to keep pro-coagulants inactive.
  • FII and FV may be stable for at least 24h at ⁇ 23°C. It is preferable to avoid freeze-thawing in any of the conditions.
  • a range between 0.1-2.0mM CaCh in the absence of chelating agents like citrate is suitable for stabilization, obtaining optimum results at 2.0mM. Exceeding this value might provoke the activation of the coagulation cascade.
  • a lyophilization process was executed.
  • 320ml of CDP (batch #W33Y 140) at pH 7.0 were loaded into a 16ml Eshmuno Q column at 200 cm/h.
  • the bound material was eluted with 56 ml of a buffer containing IM NaCl and 20mM Glycine at pH 7.2, concentrating the purified proteins 6.3 times (load/elution ratio).
  • the elution was divided into 3 aliquots: A) no calcium was added, B) added O.lmM CaCh and C) added 2mM CaCh.
  • the samples were centrifuged in a lOKDa PES Ultra Spin column (Thermo) for 5 hours between 6000-7000g at 4 °C, concentrating the protein content 11 times.
  • the samples were diluted between 1/3.8 to 1/4.3 with 20mM glycine at pH 7.2, while calcium concentration was compensated to keep the original values for A, B and C, achieving an osmolarity of 282 for A, 233 for B and 295 mOsm for C.
  • 1ml samples of the three samples were freeze-dried in 5ml vials using a Christ Freeze-dryer model Epsilon 2-8D using the method depicted in Table 8 and Fig. 10.
  • Fig. 10 shows lyophilization method.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des formulations constituées d'un facteur V concentré, d'une protéine de coagulation indépendante de la vitamine et un stabilisant, le stabilisant étant à une concentration à laquelle le facteur V ou la protéine de coagulation dépendante de la vitamine K se trouvent sous forme zymogène. L'invention concerne également des procédés de préparation des formulations.
PCT/IL2021/051112 2020-09-23 2021-09-13 Formulations hémostatiques et leurs utilisations WO2022064478A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202180064844.0A CN116194080A (zh) 2020-09-23 2021-09-13 止血制剂及其用途
AU2021348528A AU2021348528A1 (en) 2020-09-23 2021-09-13 Hemostatic formulations and uses thereof
EP21801233.4A EP4216928A1 (fr) 2020-09-23 2021-09-13 Formulations hémostatiques et leurs utilisations

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063082029P 2020-09-23 2020-09-23
US63/082,029 2020-09-23
IL277543 2020-09-23
IL27754320 2020-09-23

Publications (1)

Publication Number Publication Date
WO2022064478A1 true WO2022064478A1 (fr) 2022-03-31

Family

ID=80844583

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2021/051112 WO2022064478A1 (fr) 2020-09-23 2021-09-13 Formulations hémostatiques et leurs utilisations

Country Status (4)

Country Link
EP (1) EP4216928A1 (fr)
CN (1) CN116194080A (fr)
AU (1) AU2021348528A1 (fr)
WO (1) WO2022064478A1 (fr)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560475A (en) 1969-06-19 1971-02-02 Baxter Laboratories Inc Prothrombin complex prepared by precipitation with polyethylene glycol
US5866122A (en) 1996-03-20 1999-02-02 Immuno Aktiengesellschaft Pharmaceutical preparation for treating blood coagulation disorders
USRE38431E1 (en) 1995-12-01 2004-02-17 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US7371722B2 (en) 2002-07-23 2008-05-13 Bio & Bio Licensing S.A. Pharmaceutical preparations and medicine capable of generating and/or containing thrombin
US20090011043A1 (en) 2007-07-03 2009-01-08 Hua Xie Tissue sealant made from whole blood
WO2013116366A1 (fr) * 2012-01-30 2013-08-08 Baxter International Inc. Polysaccharides sulfatés ou sulfonés non anticoagulants
US20140155498A1 (en) 2012-10-12 2014-06-05 Leon Wortham Method of Manufacture of Stable Liquid Coagulation Factors
US20150272562A1 (en) * 2014-03-27 2015-10-01 Ethicon, Inc. Device and method for preparing and administering one-component fibrin sealant
US9814765B2 (en) 2013-12-24 2017-11-14 Ethicon, Inc. One component fibrin glue comprising zymogens
US20180036338A1 (en) 2014-12-19 2018-02-08 Baxter International Inc. Flowable hemostatic composition
US20180369346A1 (en) 2016-01-07 2018-12-27 Eio Biomedical Ltd. Methods, compositions and kits for reducing tissue adhesions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1749536A1 (fr) * 2005-08-03 2007-02-07 Thrombotargets Europe, S.L. Stimulateurs activés du Facteur X et leur utilisation en tant qu'agents anti-hemorragiques pour l'usage topique
SE1050124A1 (sv) * 2010-02-08 2011-08-09 Linkoping Biocontrols Ab Stabil lösning

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560475A (en) 1969-06-19 1971-02-02 Baxter Laboratories Inc Prothrombin complex prepared by precipitation with polyethylene glycol
USRE38431E1 (en) 1995-12-01 2004-02-17 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US5866122A (en) 1996-03-20 1999-02-02 Immuno Aktiengesellschaft Pharmaceutical preparation for treating blood coagulation disorders
US7371722B2 (en) 2002-07-23 2008-05-13 Bio & Bio Licensing S.A. Pharmaceutical preparations and medicine capable of generating and/or containing thrombin
US20090011043A1 (en) 2007-07-03 2009-01-08 Hua Xie Tissue sealant made from whole blood
WO2013116366A1 (fr) * 2012-01-30 2013-08-08 Baxter International Inc. Polysaccharides sulfatés ou sulfonés non anticoagulants
US20140155498A1 (en) 2012-10-12 2014-06-05 Leon Wortham Method of Manufacture of Stable Liquid Coagulation Factors
US9814765B2 (en) 2013-12-24 2017-11-14 Ethicon, Inc. One component fibrin glue comprising zymogens
US20150272562A1 (en) * 2014-03-27 2015-10-01 Ethicon, Inc. Device and method for preparing and administering one-component fibrin sealant
US20180036338A1 (en) 2014-12-19 2018-02-08 Baxter International Inc. Flowable hemostatic composition
US20180369346A1 (en) 2016-01-07 2018-12-27 Eio Biomedical Ltd. Methods, compositions and kits for reducing tissue adhesions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Prothrombinex -VF powder", 22 November 2018 (2018-11-22), pages 1 - 16, XP055876321, Retrieved from the Internet <URL:https://www.nzblood.co.nz/assets/Transfusion-Medicine/PDFs/160S031.pdf> [retrieved on 20220105] *

Also Published As

Publication number Publication date
CN116194080A (zh) 2023-05-30
AU2021348528A1 (en) 2023-06-08
AU2021348528A9 (en) 2024-05-30
EP4216928A1 (fr) 2023-08-02

Similar Documents

Publication Publication Date Title
CA2557061C (fr) Facteur ixa pour le traitement de troubles de saignement
Nowak et al. Quantitative determination of hirudin in blood and body fluids
JP2540541B2 (ja) 第ｖ因子濃縮物の製法
BRPI0707268A2 (pt) purificação e uso de um fator para ajudar a cura de ferimento
EP2945962B1 (fr) Procédés d&#39;isolement de produits sanguins à partir d&#39;une matière de produit sanguin appauvrie en protéine inter-alpha inhibiteur
Suomela et al. The activation of factor X evaluated by using synthetic substrates
WO2022064478A1 (fr) Formulations hémostatiques et leurs utilisations
EP2522354B1 (fr) Procédé de réduction des événements indésirables causés par les préparations pharmaceutiques comportant des protéines dérivées du plasma
US20210290738A1 (en) Fx activation process and its use in the preparation of a fxa composition
Suomela et al. Preparation and properties of a therapeutic factor IX concentrate
RU2488403C1 (ru) Способ получения особо чистого препарата ферроксидазы церулоплазмина и/или фактора свертывания крови протромбина. аффинный неомициновый сорбент для их получения
US8889624B2 (en) Thrombin-free composition containing freeze-dried, virally inactivated FXIa and serpins and/or kininogen
JP2007055899A (ja) 血液凝固第ｘ因子を主剤とする血液凝固異常に基づく疾患の治療・予防用医薬組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21801233

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021801233

Country of ref document: EP

Effective date: 20230424

ENP Entry into the national phase

Ref document number: 2021348528

Country of ref document: AU

Date of ref document: 20210913

Kind code of ref document: A